Drugs / AGS-004
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02707900 | Mar 2016 → Jul 2018 | HIV infectious disease | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 1 | NCT02042248 | Mar 2014 → May 2016 | HIV infectious disease | Cynthia L Gay, MD | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00381212 | Sep 2006 → Feb 2008 | AIDS | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01069809 | Jul 2010 → Aug 2014 | HIV infectious disease | Argos Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00672191 | Feb 2008 → Aug 2010 | HIV infectious disease | Argos Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-07-22 | Bionor Immuno AS | Results BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV bionorholding.com ↗
Also in a Phase 2 trial, AGS-004 from Argos Therapeutics showed large reductions in viral loads, allowing extended ART holidays for treatment-experienced patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-07-22 | Bionor Immuno AS | BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV bionorholding.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01069809 ↗ |
| Known as | Argos (AGS)-004 | “successful production of Argos (AGS)-004 product” NCT02042248 ↗ |
| Modality | Cell therapy | “AGS-004 is an immunotherapeutic agent made from autologous DCs” NCT00672191 ↗ |
| Route | Other | “three ID (intradermal) injections” NCT02042248 ↗ |